Search Results - "Leal, Jorge Henrique Santos"

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading by Force, Jeremy, Leal, Jorge Henrique Santos, McArthur, Heather L.

“…Opinion Statement Immunotherapy has become one of the greatest advances in medical oncology over the last century; however, the optimal application for the…”
Get full text

Taste disorders following cancer treatment: report of a case series by Epstein, Joel B., de Andrade e Silva, Safira Marques, Epstein, Geena L., Leal, Jorge Henrique Santos, Barasch, Andrei, Smutzer, Gregory

“…Purpose To present the findings of combined oral assessment and gustometry testing of a series of head and neck and hematologic malignancies in patients with…”
Get full text

Breast Cancer Immunotherapy: From Biology to Current Clinical Applications by Leal, Jorge Henrique Santos, McArthur, Heather

“…Therapeutic strategies for the treatment of breast cancer have historically been determined by the presence or absence of hormone receptors and HER2…”
Get full text

Abstract PO3-05-03: Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE study - LACOG 0221) by Werutsky, Gustavo, Rosa, Daniela, Reinert, Tomás, Barroso-Sousa, Romualdo, Resende, Heloísa, Signorini, Poliana, Cronenberger, Eduardo, Fagundes, Juliana Góes Martins, Leal, Jorge Henrique Santos, Giffoni, Marina Dutra, Vieira, Aline, Weis, Luiza Nardin, Figueiredo, Jose Marcio, Correa, Tatiana, Venero, Fernando Castilho, Franche, Luisa Mostardeiro Tabajara, Bernardes, Marina Musse, Jesus, Rafaela, Gössling, Gustavo, Bines, José

“…Introduction: Endocrine therapy (ET) plus CDK 4/6 inhibitors is considered the standard of care as first-line therapy in hormone receptor positive (HR+)/HER2…”
Get full text

Abstract PO5-19-07: A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer by McArthur, Heather, Comen, Elizabeth, Bryce, Yolanda, Solomon, Stephen, Reddy, Sangeetha, Chan, Isaac, Dogan, Baṣak, Klemow, Dawn, Unni, Nisha, Leal, Jorge Henrique Santos, Martinez, Cristal, Basho, Reva, Park, Dorothy, McAndrew, Philomena, Larkin, Brigid, Page, David, Mills, William, Mellinger, Staci, Fredrich, Nicole, Moxon, Nicole, Currie, Lynette, Carter, Meredith, Ramos, Melissa, Rice, Stephanie, Patil, Sujata, Gatti-Mays, Margaret, Norton, Larry

“…Background: Triple negative breast cancer (TNBC) is a biologically distinct subtype with a high risk of early relapse. Patients not achieving a pathological…”
Get full text

Abstract PO5-19-08: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial by McArthur, Heather, Leal, Jorge Henrique Santos, Chan, Isaac, Unni, Nisha, Shiao, Stephen, Gruber, Joshua, Syed, Samira, Peswani, Namrata, Sadeghi, Navid, Delgado, Glenda, Klemow, Dawn, Basho, Reva, Carter, Meredith, Badran, Mai, Qureshi, Nasir, Curtin, Jessica, Weese, Joshua, Rice, Stephanie, Phillips, Michelle, Chan, David, Hool, Hugo, Park, Dorothy, El-Masry, Mary, McAndrew, Philomena, Sikaria, Swati, Spring, Laura, Bardia, Aditya, Tighiouart, Mourad, Dadmanesh, Farnaz, Giuliano, Armando, Sanchez, Katherine, Page, David

“…Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI…”
Get full text

Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial by McArthur, Heather, Leal, Jorge Henrique Santos, Abaya, Christina DiLauro, Reddy, Sangeetha, Carter, Meredith, Basho, Reva, Phillips, Michelle, Chan, David, Hool, Hugo, Park, Dorothy, El-Masry, Mary, McAndrew, Philomena, Sikaria, Swati, Spring, Laura M., Bardia, Aditya, Tighiouart, Mourad, Dadmanesh, Farnaz, Giuliano, Armando, Shiao, Stephen, Page, David B.

“…Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI…”
Get full text

Abstract OT1-19-01: A Single Arm Phase 2 Study of Peri-Operative Checkpoint-Mediated Immune Therapy and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer by McArthur, Heather, Comen, Elizabeth, Bryce, Yolanda, Solomon, Stephen, Leal, Jorge Henrique Santos, Abaya, Christina DiLauro, Martinez, Cristal, Basho, Reva, Park, Dorothy, McAndrew, Philomena, Larkin, Brigid, Mills, William, Page, David B., Mellinger, Staci, Fredrich, Nicole, Moxon, Nicole, Reddy, Sangeetha, Carter, Meredith, Patil, Sujata, Norton, Larry

“…Background: Local tumor destruction with cryoablation (cryo) induces inflammation and releases antigens that can activate tumor-specific immune responses…”
Get full text

Abstract OT3-07-01: Real-World Data on First-line Treatment of HR-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE Study/LACOG 0221) by Werutsky, Gustavo, Reinert, Tomás, Rosa, Daniela D., Barroso-Sousa, Romualdo, Resende, Heloísa, Signorini, Poliana A., Fagundes, Juliana G. Martins, Figueiredo, Jose Marcio B., Cronemberger, Eduardo, Vieira, Aline C., Leal, Jorge Henrique Santos, Weis, Luiza Nardin, Thommen, Ludmila, Jesus, Rafaela G., Gössling, Gustavo, Bines, José

“…Background: It is estimated that 50 thousand patients live with metastatic breast cancer (MBC) in Brazil. A recent Brazilian registry (LACOG 0312) on MBC…”
Get full text